N-methyl-N-isopropyltryptamine (MiPT) is a
psychedelictryptamine, closely related to
DMT,
DiPT and
miprocin. It was first synthesized by David Repke in 1984[1] and was subsequently evaluated and described in Alexander Shulgin's 1997 book
TiHKAL.
Chemistry
MiPT is the N-isopropyl analog of DMT and the N-methyl analog of DiPT.
In August 2019, Chadeayne et al. solved the crystal structure of fumarate salt of MiPT.[2]
Dosage
Moderate effects have been reported at 10-25
mg ingested
orally, with effects lasting 4–8 hours. One of the test subjects in TiHKAL reported moderate effects at 20 mg ingested
intranasally.[3]
Effects
In TiHKAL,[4] the subjective experience is reported to be biased towards mental (
psychedelic/
entheogenic) effects, with mild perceptual (
sensory/
hallucinogenic) alterations relative to other tryptamines.[3] Subjects reported enhancement of the visual field (brightened and modulated color perception) but a lack of visual distortion typical of tryptamines such as psilocin. Enhancement of auditory perception was also noted. Documented physical effects include stimulation, dry mouth, and muscle tension.
Legality
In the United States, MiPT is unscheduled but purchase, sale, or possession for human consumption could be prosecuted under the
Federal Analogue Act.[5] MiPT is specifically mentioned in the
DEAOrange Book.[6]
Sweden's public health agency suggested classifying MiPT as a hazardous substance, on May 15, 2019.[7]
^Glennon RA, Jacyno JM, Young R, McKenney JD, Nelson D (January 1984). "Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines". Journal of Medicinal Chemistry. 27 (1): 41–45.
doi:
10.1021/jm00367a008.
PMID6581313.
N-methyl-N-isopropyltryptamine (MiPT) is a
psychedelictryptamine, closely related to
DMT,
DiPT and
miprocin. It was first synthesized by David Repke in 1984[1] and was subsequently evaluated and described in Alexander Shulgin's 1997 book
TiHKAL.
Chemistry
MiPT is the N-isopropyl analog of DMT and the N-methyl analog of DiPT.
In August 2019, Chadeayne et al. solved the crystal structure of fumarate salt of MiPT.[2]
Dosage
Moderate effects have been reported at 10-25
mg ingested
orally, with effects lasting 4–8 hours. One of the test subjects in TiHKAL reported moderate effects at 20 mg ingested
intranasally.[3]
Effects
In TiHKAL,[4] the subjective experience is reported to be biased towards mental (
psychedelic/
entheogenic) effects, with mild perceptual (
sensory/
hallucinogenic) alterations relative to other tryptamines.[3] Subjects reported enhancement of the visual field (brightened and modulated color perception) but a lack of visual distortion typical of tryptamines such as psilocin. Enhancement of auditory perception was also noted. Documented physical effects include stimulation, dry mouth, and muscle tension.
Legality
In the United States, MiPT is unscheduled but purchase, sale, or possession for human consumption could be prosecuted under the
Federal Analogue Act.[5] MiPT is specifically mentioned in the
DEAOrange Book.[6]
Sweden's public health agency suggested classifying MiPT as a hazardous substance, on May 15, 2019.[7]
^Glennon RA, Jacyno JM, Young R, McKenney JD, Nelson D (January 1984). "Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines". Journal of Medicinal Chemistry. 27 (1): 41–45.
doi:
10.1021/jm00367a008.
PMID6581313.